|
|
|
|
| LEADER |
00000cam a2200000 c4500 |
| 001 |
1114550094 |
| 003 |
DE-627 |
| 005 |
20230427080641.0 |
| 007 |
tu |
| 008 |
950328s1993 xx ||||| t 00| ||eng c |
| 035 |
|
|
|a (DE-627)1114550094
|
| 035 |
|
|
|a (DE-576)04455009X
|
| 035 |
|
|
|a (DE-599)BSZ04455009X
|
| 035 |
|
|
|a (OCoLC)312317360
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 088 |
|
|
|a GAO GGD 94-7
|
| 245 |
1 |
0 |
|a Drug control
|n Test
|p Testimony before the Legislation and National Security Subcommittee, Committee on Government Operations, House of Representatives / Statemment of Henry R. Wray
|c United States General Accounting Office
|
| 264 |
|
1 |
|a Washington, DC
|c 1993
|
| 300 |
|
|
|a 18 S.
|b graph. Darst.
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 583 |
1 |
|
|a Archivierung prüfen
|c 20200919
|f DE-640
|z 1
|2 pdager
|
| 655 |
|
7 |
|a Forschungsbericht
|0 (DE-588)4155043-2
|0 (DE-627)10467444X
|0 (DE-576)209815833
|2 gnd-content
|
| 700 |
1 |
|
|a Wray, Henry R.
|4 oth
|
| 773 |
1 |
8 |
|a Drug control reauthorization of the Office of National Drug Control Policy
|w (DE-627)1114549665
|w (DE-576)044549660
|g (Test)
|q test
|7 nnnm
|
| 951 |
|
|
|a MV
|
| ELC |
|
|
|b 1
|
| LOK |
|
|
|0 000 xxxxxcx a22 zn 4500
|
| LOK |
|
|
|0 001 2252783621
|
| LOK |
|
|
|0 003 DE-627
|
| LOK |
|
|
|0 004 1114550094
|
| LOK |
|
|
|0 005 19960221000000
|
| LOK |
|
|
|0 008 950328||||||||||||||||ger|||||||
|
| LOK |
|
|
|0 040
|a DE-21
|c DE-627
|d DE-21
|
| LOK |
|
|
|0 852
|a DE-21
|
| LOK |
|
|
|0 852 1
|c KB 3 B 231-2
|9 00
|
| LOK |
|
|
|0 935
|a krim
|
| LOK |
|
|
|0 936ln
|a k9.7.2.2
|
| ORI |
|
|
|a SA-MARC-krimdoka001.raw
|
| SIG |
|
|
|a UB: KB 3 B 231-2
|
